Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2022 - 01 - 06 save search
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 1.94%
H: 0.48%
C: -4.76%
trial topline results positive therapy linzagolix topline phase 3
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 4.66%
H: 2.34%
C: 2.34%
genetic trial cel phase 1 therapy t-cell glioblastoma
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy
Published: 2022-01-06 (Crawled : 13:30) - biospace.com/
CRIS | $14.705 -2.03% -2.07% 4.7K
|
Health Technology
|
| O: -2.28%
H: 1.69%
C: -25.95%
ca-4948 phase 1 therapy phase 2
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: -3.32%
novartis announces collaboration liver therapy collaboration
REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.94%
H: 1.03%
C: -1.47%
rgx-202 fda muscular dystrophy clearance gene therapy trial fda clearance duchenne therapy
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-06 (Crawled : 12:30) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K
|
Health Technology
|
| O: -1.38%
H: 2.52%
C: 1.77%
health thc conference gene therapies j.p. morgan healthcare conference gene therapy therapy
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
Published: 2022-01-06 (Crawled : 12:00) - biospace.com/
BRTX | $1.26 -5.97% -6.35% 75K
|
Professional, Scientific, and T...
|
| O: -2.92%
H: 27.14%
C: 11.83%
conference therapy
Genprex to Participate in January 2022 Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
Published: 2022-01-05 (Crawled : 10:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -13.14%
H: 0.0%
C: 0.0%
health thc conference diabetes gene therapies cancer gene therapy therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.